zum Directory-modus

Autoimmune Diagnostics

Serological Diagnosis of Rheumatoid Arthritis

In addition to rheumatoid factor the detection of ACPAs (ACPA stands for anti-citrullinated protein/peptide antibody) has become a standard procedure in the diagnosis of rheumatoid arthritis (RA) and has recently been included in the updated official criteria for classification of rheumatoid arthritis defined by the ACR (American College for Rheumatology)1,2,3,. The use of ACPAs allows physicians to predict the progression of the disease4,5), and some of these autoantibodies also seem to be a good and objective measurement of disease activity and the effectiveness of treatment for rheumatoid arthritis6,7). If these early results from international studies are borne out, this would be a significant step forward for the diagnosis and treatment of rheumatoid arthritis, which is the most common autoimmune disease overall and affects nearly one percent of the world's population.

It is known that certain ACPAs are directly involved in the development of rheumatoid arthritis, in that they bind to components of the body's own articular cartilage8). This attracts scavenger cells, which release inflammatory signal substances like tumor necrosis factor-alpha and interleukins, as well as joint-degrading enzymes like elastase and other proteases. This causes a flare up of inflammation, which the body can no longer control. The result is fatal: the joints are eventually destroyed.

Antibody specific for citrullinated collagen

Antibody ACC4 specific for citrullinated collagen type II (PDB code: 2W65).

Antibody chain A / B / C / D: green / brown / light blue / silver; collagen derived peptide PCII-CIT1: blue; citrulline: orange.

1)Feist, E.; Egerer, K.; Burmester, G. R. (2007): Autoantikörperprofile bei der rheumatoiden Arthritis [Autoantibody profile in rheumatoid arthritis]. In: Z Rheumatol.. 66 (3) , 212-8
2) Gross, W. L.; Moosig, F.; Lamprecht, P. (2009): Anti-Citrullinated Protein-Peptide Antibodies in Rheumatoid Arthritis [Anticitrullinierte Protein/Peptid-Antikörper bei rheumatoider Arthritis]. In: Dtsch Arztebl Int.. 106 (10) , 157-158
3) Aletaha, D.; et al., . (2010): 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative.. In: Ann. Rheum. Dis.. 69 (9) , 1580-8
4) Mathsson, L.; Mullazehi, M.; Wick, M. C.; Sjoberg, O.; van Klareskog, V. R. (2007): Antibodies against citrullinated vimentin in rheumatoid arthritis: Higher sensitivity and extended prognostic value concerning future radiographic progression as compared with antibodies against cyclic citrullinated peptides.. In: Arthritis Rheum.. 58 (1) , 36-45
5) Luime, J. J.; Colin, E. M.; Hazes, J. M. W.; Lubberts, E. (2008): Does anti-MCV has additional value as serological marker in the diagnostic and prognostic work-up of patients with rheumatoid arthritis? A systematic review (published online).. In: Ann Rheum Dis.. ,
6) Bang, H.; Egerer, K.; Gauliard, A.; Lüthke, K.; Rudolph, P. E.; Fredenhagen, G.; Berg, W.; Feist, E.; Burmester, G. R. (2007): Mutation and citrullination modifies vimentin to a novel autoantigen for rheumatoid arthritis.. In: Arthritis Rheum.. 56 (8) , 2503-11
7) Roland, P. N.; Mignot, S. G.; Bruns, A.; Hurtado, M.; Palazzo, E.; Hayem, G.; Dieudé, P.; Meyer, O.; Martin, S. C. (2008): Antibodies to mutated citrullinated vimentin for diagnosing rheumatoid arthritis in anti-CCP-negative patients and for monitoring infliximab therapy.. In: Arthritis Res Ther.. 10 (6) , R142
8) Klareskog, L.; Widhe, M.; Hermansson, M.; Rönnelid, J. (2008): Antibodies to citrullinated proteins in arthritis: pathology and promise.. In: Curr Opinion Rheumatol.. 20 (3) , 300-5
Page 5 of 13